1. The use of a humanized antibody or antigen binding fragment thereof that binds to the CD19 antigen for the treatment of multiple sclerosis (MS), in which, if necessary, a therapeutically effective amount of such an antibody is administered to the individual. The use according to claim 1, characterized in that multiple sclerosis is selected from the group consisting of relapsing-remitting (RR) MS, primary-progressing (PP) MS, secondary-progressing (SP) MS, and relapsing-progressing (RP) MS and progressive Recurrent (PR) MS. 3. The use of claim 2, wherein the multiple sclerosis is (i) RRMS or (ii) a progressive form of MS selected from PPMS, SPMS and PRMS. 4. The use according to claim 1, characterized in that the antibody contains VH and VL, wherein VH contains CDR1 VH, which is at least 95% identical to the amino acid sequence of SEQ ID NO: 1, CDR2 VH, which is at least 95% identical to the amino acid sequence SEQ ID NO: 2, and CDR3 VH, which is at least 95% identical to the amino acid sequence of SEQ ID NO: 3.5. The use of claim 4, wherein the antibody contains VH and VL, wherein VH contains CDR1 VH with the amino acid sequence of SEQ ID NO: 1, CDR2 VH with the amino acid sequence of SEQ ID NO: 2 and CDR3 VH with the amino acid sequence of SEQ ID NO: 3.6. The use of claim 1, wherein the antibody contains VH and VL, wherein VL contains CDR1 VL, which is at least 95% identical to the amino acid sequence of SEQ ID NO: 4, CDR2 VL, which is at least 95% identical to the amino acid sequence SEQ ID NO: 5, and CDR3 VL, which is at least 95% identical to the amino acid sequence of SEQ ID NO: 6.7. The use according to claim 6, characterized in that the antibody contains VH and VL, wherein the VL contains CDR1 VL with the amino acid sequence of SEQ ID NO: 4, CDR2 VL with the amino acid sequence of SEQ ID NO: 5 and CDR3 VL with the amino acid1. Применение гуманизированного антитела или его антигенсвязующего фрагмента, который связывается с антигеном CD19, для лечения рассея
